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Mixed urinary incontinence (MUI),  defined as  mixed symptoms of  stress
urinary  incontinence  (SUI)  and  overactive  bladder  (OAB),  is  a  difficult
entity  if  conservative  treatment  has  failed.  Cure  rates  are  low compared
with  SUI,  particularly  the  OAB  component,  may  deteriorate  after  sling

















































MUI. They have shown beneficial  effect in small case studies,  but larger
series  are  lacking.  The  aim of  this  prospective  study was  an  analysis  of
treatment  efficacy  and  safety  profile  of  the  bulking  agent,  Bulkamid,  in
female patients with MUI.
Methods
One  hundred  fifty-four  women  with  MUI  symptoms  (components  of
SUI/OAB within the limits of 60–40% either way) received bulking therapy
with  polyacrylamide  hydrogel  (Bulkamid).  Patients  were  followed-up
3 months postoperatively.  Primary outcome was the domain Incontinence
impact  on  the  King’s  Health  Questionnaire  (KHQ).  Secondary  outcomes
were the other KHQ domains, visual analog scale (VAS), and International
Continence  Society  (ICS)  standardized  pad  weight  test  as  objective
measurement of incontinence.
Results
Statistically  significant  improvements  were  found  for  all  KHQ domains,
pad weight test, and the visual analog scale (VAS) before and after bulking.
Overall complication rate was 13%.
Conclusions
This study has shown improvement in MUI after bulking therapy according
to  both  subjective  and  objective  outcomes.  We  can  advocate  bulking
therapy for treating MUI, as it is simple and safe and shows both objective
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Introduction
Mixed urinary incontinence (MUI) is defined as involuntary loss of urine
associated with urgency and with effort, physical exertion, sneezing, or
coughing [ 1 ]. It is a combination of stress urinary incontinence (SUI) and
overactive bladder (OAB) and is prevalent in 20–36% of women [ 2 ]. The
pathophysiology of MUI is poorly understood, which impedes choosing
appropriate therapies [ 2, 3 ]. Treatment is controversial, and an individual
strategy is needed, since women with MUI comprise a heterogenous group of
patients [ 4 ]. Initially, a conservative approach is advocated [ 4 ], treating the
most bothersome component first [ 2 ]. If surgery is needed, urodynamic
evaluation is recommended [ 4 ], although the role of urodynamics in MUI is
also controversial [ 5 ].
Retropubic colposuspension is effective for treating SUI, but de novo urge
and a higher risk of pelvic organ prolapse (POP) are known side effects [ 6 ].
Midurethral slings are safe and efficacious treatment options [ 7 ].
Transobturator tape seem to have a good subjective success rate, and
frequently, urgency urinary incontinence (UUI) resolves [ 8 ]. The main reason
for dissatisfaction with a sling in general is overactive bladder [ 9 ]. Even if
SUI is cured surgically, patients need to be informed that OAB symptoms
might persist or even deteriorate [ 4 ].
Evidence is available for treating UI with weight loss, SUI with slings and
urethropexies, and UUI with anticholinergics. However, there are neither clear
diagnostic criteria nor management guidelines for MUI, and evidence for
treatment is lacking [ 2 ]. Hence, treatment alternatives are required in patients
with MUI. Peri- or transurethral bulking is a simple method to treat
incontinence in a subset of patients showing objective and subjective
symptom improvement [ 10 ], and Bulkamid has favorable results in a pooled
population of SUI and MUI [ 11 ]. The aim of this study was to specify the
efficacy of the periurethral bulking agent Bulkamid (polyacrylamide
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hydrogel; PAHG) in patients with exclusive MUI.
Materials and methods
Between January 2010 and October 2014, 154 women with MUI were treated
by periurethral bulking with polyacrylamid hydrogel (PAHG; Bulkamid) in
the University Women’s Hospital, Department of Urogynecology, Bern,
Switzerland, and the Princess Anne Hospital, Department of Urogynecology,
Southhampton, UK. To be included in the study, components of SUI and OAB
had to be within the limits of 60–40% either way to avoid predominance of
one aspect. This is in contrast to our previous study in which only patients
with SUI were included [ 10 ]. Primary outcome was the domain of
Incontinence impact of the King’s Health Questionnaire (KHQ). Secondary
outcomes were the remaining domains, visual analogue scale (VAS), and
International Continence Society (ICS) standardized pad test as objective
measurements of incontinence. Subjective and objective outcomes were
measured before and 3 months after intervention. To gather a rather
homogenous group of patients with balanced MUI, they rated the stress and
OAB components of their bladder problem with the limits of 60:40% to either
side. Demographic data of age, body mass index (BMI), parity, and
menopausal status were noted. The study was approved by the local ethical
committee, and all patients gave informed consent to participate (KEK
127/2009).
The King’s Health Questionnaire (KHQ) determines quality of life (QoL) and
is widely used in patients with incontinence [ 12 ]. The questionnaire is
validated in several languages, including German [ 13 ], and is used to assess
various domains, including general health perception, role limitation (e.g.,
household, cleaning, shopping), physical and personal limitation (walking,
sports, travel, social life, relationship, sex, family life), emotions (depressed,
anxious, nervous, feeling bad about oneself), sleep (feeling worn out, tired),
and incontinence impact (pad usage, need to change underwear, restrict
drinking, fear bad smells). Additionally, bladder problems are specified in the
KHQ as questions for frequency symptoms, nocturia, urgency, SUI episodes,
coital incontinence, urinary tract infections (UTI), and bladder pain exist. The
scores for each domain range from 0 to 5 and 1 to 5, respectively, are totalled,
and a change of at least five points is considered significant [ 13 ]. Subjective
outcome was further assessed with the patients judging their incontinence
severity on a visual analogue scale (VAS), a validated tool to assess health
and satisfaction, pain, attitudinal attributes, and QoL [ 14 ].
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Additionally, as objective measurements, a standardized 2-h in-office pad test
was performed according to ICS recommendations [ 15 ]. Before and after
intervention, UTIs were excluded using dipstick screening and infections or
bacteriuria was treated. For the injection procedure, women were placed in
the lithotomy position, 5–10 ml of 1% lidocaine were injected in the
periurethral tissue at 4 and 8 o’clock, and the bulking agent was injected
transurethrally into the submucosa under cystoscopic control. Two to three
deposits were placed in the midurethra at 6, 2, and 10 o’clock, and quantity
was determined by the surgeon’s judgement of coaptation. Needle position
was corrected if it was suspected to not be in the mucosa or if there was
extravasation of the bulking agent. If coaptation was considered appropriate,
the bladder was emptied. Patients received a single-shot antibiotic
prophylaxis with Co-amoxicillin and were discharged if postmicturition
residual volume was <100 ml. Evaluation was performed 3 months
postoperatively. All adverse events were monitored and registered. If the
procedure was unsuccessful, the woman was offered a further injection after
6 weeks. For statistical analysis, Graph Pad Prism version 5.0 for Windows
was used (Graph Pad, La Jolla, CA, USA) to calculate Student’s t test and
Wilcoxon signed rank test.
Results
One hundred and fifty-four patients were injected with Bulkamid
periurethrally. Demographic data demonstrated a median age of 68 (range
29–93) years, a median BMI of 24 kg/m  (range 17–32), and a median parity
of two (range 0–9). Seven patients were pre-, six peri-, and 141
postmenopausal. For 12 patients, menopausal status was lacking. In our
collective, 11 patients had previously undergone Burch colposuspension, nine
a retropubic sling, and three a transobturator sling. Sixteen patients were lost
to follow-up, whereof two died of unrelated causes, 12 moved to other places,
and two were lost because of unknown reasons. Analysis with the Wilcoxon
signed-rank test for non-normally distributed paired data showed statistically
significant improvements for all domains of the KHQ before and after bulking
(Fig. 1 , all p < 0.0001). Likewise, pad-weight test (Fig. 2 , p < 0.0001), and
the VAS as a sujective measure of severity (Fig. 3 , p < 0.0001) improved
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Results  of  the  King’s  Health  Questionnaire:  all  domains  were  significantly
improved after bulking therapy (p < 0.001, Wilcoxon signed rank test)
Fig. 2
Pad-weight test results improved significantly after bulking therapy (p < 0.001,
Wilcoxon signed-rank test)
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Fig. 3
Visual Analogue Scale results as a subjective measure of incontinence severity
with a significant improvement (p < 0.001, Wilcoxon Signed Rank Test)
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The overall complication rate was 13% due to lower UTIs (n = 12), temporary
retention <48 h (n = 3), and pain requiring additional pain medication (n = 4).
Discussion
We show that bulking therapy is a beneficial and valuable alternative to
surgical treatment in the rather heterogenous group of patients with MUI.
Pad-weight tests showed that patients were not dry after the injections but that
leakage was significantly improved, and their satisfaction mirrors QoL
improvement on the VAS and KHQ results. Additionally, it also suggests that
patient satisfaction is not necessarily dependant on complete dryness.
In MUI, treatment decisions are less obvious than in either SUI or UUI
patients, and alternative therapies are needed [ 2 ]. Periurethral bulking therapy
has been used for for years to treat SUI and shows improvements even over
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the long term [ 16 ]. Recurrence rates are higher after bulking therapy than
after other incontinence surgeries but should be considered as an alternative
treatment [ 17 ]. Bulking therapy is simple, safe, and shows both objective and
subjective improvement and relief in selected SUI patients [ 10 ]. Although a
Cochrane Review concluded that evidence for urethral injection therapy to
treat UI in women remains insufficient to guide practice [ 18 ], the minimally
invasive nature, efficacy, and safety of periurethral bulking with PAHG favors
its use in the correctly selected patient [ 19, 20, 21 ].
Moreover, bulking therapy is used to manage failed SUI surgery [ 22, 23 ],
especially in patients with intrinsic sphincter deficiency [ 24 ], and PAHG is
used in this respect with good outcome and low complication rates [ 24, 25 ].
Repeat midurethral sling after primary sling failure seems to have a lower risk
of failure than bulking therapy [ 26 ], but the latter is more cost effective than
midurethral slings in patients without urethral hypermobility [ 27 ].
Furthermore, urethral bulking therapy has been described as a valuable
treatment option in SUI after pelvic radiotherapy [ 28 ].
In MUI, conservative treatment focusing on the most bothersome component
is the first therapeutic step [ 2, 4 ]. If conservative treatment fails, surgical
alternatives become necessary. Petros suggested that in MUI, uncoupling urge
from stress might separate two different symptoms with possibly different
etiologies, and these should therefore be treated separately [ 29 ]. However,
our results suggest that bulking therapy might ameliorate incontinence
symptoms holistically. We show significant improvements in both subjective
(VAS, KHQ) and objective (pad-weight test) outcomes. Patient-reported
outcomes are particularly important, as they better reflect patient satisfaction
than do mere objective measurements [ 30 ]. Although complications of
bulking therapy are not to be neglected [ 30 ], side effects were few and mild.
Additionally, bulking therapy is minor surgery, with the possibility of using
local anaesthetic only, which is usually appreciated by patients.
Strengths of this study are the rather large number of patients, especially as it
is the first concentrating on bulking therapy in MUI patients specifically.
Advantageous is the inclusion of both objective and subjective outcomes
obtained with validated tools, since this might more accurately reflect the
patient’s goals [ 10 ].
A weakness of this work is the lack of urodynamic data measuring bladder
function before and after treatment; however, we felt urodynamic data were
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not of great importance in this study. Also, due to the strict inclusion criteria,
particularly with the mixture of SUI and OAB being relatively equal, the
study was lengthy. By incorporating urodynamics, recruiting patients
requiring invasive tests may have lengthened that period. We felt such
information—except possibly in patients with detrusor overactivity—was
unnecessary for our study. A further weakness is the lack of accurate
estimation of the influence of bulking therapy on the urge component. VAS
was used to reflect global disturbance for assessing incontinence severity in
general. Results of our study do not allow a breakdown of urge and stress
components; however, they allow us to make the conclusion that incontinence
symptoms generally improve with bulking therapy, even in patients with MUI
symptoms.
In conclusion, MUI patients are difficult to treat, since their symptoms are
heterogenous and less well understood in general. Randomized trials in
women with MUI are needed [ 2 ]. Nevertheless, bulking therapy is promising,
simple, safe, and provides patient relief. Therefore, we can recommend its use
to treat patients with MUI.
Compliance with ethical standards
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